The effect of epidermal growth factor and IGF-I infusion on hepatic and renal expression of the IGF-system in adult female rats

in Journal of Endocrinology
Authors:
JW van Neck
Search for other papers by JW van Neck in
Current site
Google Scholar
PubMed
Close
,
EM Berghout
Search for other papers by EM Berghout in
Current site
Google Scholar
PubMed
Close
,
L Vinter-Jensen
Search for other papers by L Vinter-Jensen in
Current site
Google Scholar
PubMed
Close
,
CA Groffen
Search for other papers by CA Groffen in
Current site
Google Scholar
PubMed
Close
,
V Cingel
Search for other papers by V Cingel in
Current site
Google Scholar
PubMed
Close
,
NF Dits
Search for other papers by NF Dits in
Current site
Google Scholar
PubMed
Close
,
SL Drop
Search for other papers by SL Drop in
Current site
Google Scholar
PubMed
Close
, and
A Flyvbjerg
Search for other papers by A Flyvbjerg in
Current site
Google Scholar
PubMed
Close
Free access

Sign up for journal news

Systemic administration of epidermal growth factor (EGF) in neonatal rats results in reduced body weight gain and decreased circulating levels of IGF-I, suggesting its involvement in EGF-induced growth retardation. We investigated the effect of EGF and/or IGF-I administration for 7 days on circulating IGF-I and IGFBP levels and hepatic and renal IGF-system mRNA expression profiles in adult female rats. EGF administration (30 microg/rat/day) did not influence body weight, liver or kidney weight. In contrast, IGF-I (400 microg/rat/day) and EGF/IGF-I administration increased both body weight and kidney weight. Also, serum IGF-I and the 30 kDa IGFBPs (IGFBP-1 and -2) were significantly increased in these groups. Serum IGFBP-3 levels increased in the IGF-I group along with increased hepatic IGFBP-1 and -3 mRNA levels. In contrast, in the EGF administration group serum IGFBP-3 levels were significantly decreased; however, the mRNA levels remained unchanged. In the EGF/IGF-I administration group, serum IGF-I and IGFBP-3 levels were significantly lowered when compared with the IGF-I administration group. This was in contrast to the effect on kidney weight increase that was identical for the IGF-I and EGF/IGF-I groups. The decrease in serum IGFBP-3 was not reflected at the hepatic IGFBP-3 mRNA level. IGFBP-3 expression might be regulated at a post-transcriptional level although EGF induced IGFBP-3 proteolysis could not be demonstrated in vitro. We conclude that EGF administration reduced serum IGFBP-3 whereas IGF-I administration increased the level of IGFBP-3 and IGF-I and resulted in an increased body and kidney weight in adult female rats.

 

  • Collapse
  • Expand